Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: A novel therapeutic drug for sleep disorders

CNS Neuroscience and Therapeutics

Volumn 15, Issue 1, 2009, Pages 32-51

  Miyamoto, Masaomi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Insomnia; Melatonin; MT1 receptor; MT2 receptor; Ramelteon; Suprachiasmatic nucleus (SCN); TAK 375

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; DIAZEPAM; FLUMAZENIL; HYPNOTIC SEDATIVE AGENT; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MORPHINE; RAMELTEON; TRIAZOLAM; ZOLPIDEM;

COGNITIVE DEFECT; DIZZINESS; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERANCE; FATIGUE; HANGOVER; HEADACHE; HUMAN; INSOMNIA; MOTOR DYSFUNCTION; NONHUMAN; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; SLEEP STAGE; SLEEP TIME; SOMNOLENCE; SUPRACHIASMATIC NUCLEUS; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; CIRCADIAN RHYTHM; ELECTROENCEPHALOGRAPHY; HUMANS; INDENES; LEARNING; MEMORY; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; REWARD; SLEEP DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 60349099515     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00066.x     Document Type: Review

References (108)

1. Silber MH. Chronic insomnia. N Engl J Med 2005 353 : 803 810.
2. Lamberg L. Several sleep disorders reflect gender differences. Psychiatr News 2007 42 : 40.
3. Cohn MA. Hypnotics and the control of breathing: review. Br J Pharmacol 1983 16 : 245S 250S.
4. Mitler MM. Nonselective and selective benzodiazepine receptor agonists - where are we today? Sleep 2000 23 : S39 S47.
5. Roache JD, Griffiths RR. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse ability. J Pharmacol Exp Ther 1985 234 : 120 133.
6. Barbera J, Shapio C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 2005 28 : 301 308.
7. Griffiths RR, Sannerud CA, Ator NA, Brady JV. Zolpidem behavioral pharmacology in baboons: Self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 1992 260 : 1199 1208.
8. Liappas IA, Malitas PN, Dimopoulos NP, Gitsa OE, Liappas AI, Nikolaou CK, Christodoulou GN. Zolpidem dependence case series: Possible neurobiological mechanisms and clinical management. J Psychopharmacol 2003 17 : 131 135.
9. Preston GC, Ward CE, Broks P, Traub M, Stahl SM. Effects of lorazepam on memory, attention and sedation in man: Antagonism by Ro 15-1788. Psychopharmacology 1989 97 : 222 227.
10. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B. Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994 18 : 355 372.
11. Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 2000 15 : 141 152.
12. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003 26 : 261 282.
13. Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan PM, Mangano R. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000 20 : 328 337.
14. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: A double-blind, randomized comparison with placebo. Sleep 1995 18 : 246 251.
15. Krystal AD, Wash JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003 26 : 793 799.
16. Roth T, Soubrane C, Titeux L, Wash JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006 7 : 397 406.
17. Farber RH, Burke PJ. Post-bedtime dosing with indiplon in adults and the elderly: Results from two placebo-controlled, active comparator crossover studies in healthy volunteers. Curr Med Res Opin 2008 24 : 837 846.
18. Rush CR, Frey JM, Griffith RR. Zaleplon and triazolam in humans: Acute behavioral effects and abuse potential. Psychopharmacology (Berl) 1999 145 : 39 51.
19. Vermeeren A. Residual effects of hypnotics: Epidemiology and clinical implications. CNS Drugs 2004 18 : 297 328.
20. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000 4 : 551 581.
21. Evans SM, Funderburk FR, Griffith RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990 255 : 1246 1255.
22. Griffiths RR, Johnson MW. Relative abuse ability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005 66 : 31 41.
23. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: A review of case reports and epidemiological data. Addiction 2003 98 : 1371 1378.
24. Borbély AA, Mattmann P, Loepfe M, Strauch I, Lehmann D. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 1985 4 : 189 194.
25. Brunner DP, Dijk DJ, Munch M, Borbély AA. Effect of zolpidem on sleep and sleep EEG spectra in healthy young men. Psychopharmacology (Berl) 1991 104 : 1 5.
26. Feige B, Volderholzer U, Riemann D, Hohagen F, Berger M. Independent sleep EEG slow-wave sleep and spindle band dynamics associated with 4 weeks of continuous application of short-half-life hypnotics in healthy subjects. Clin Neurophysiol 1999 110 : 1965 1974.
27. Rosenburg R, Caron J, Roth T, Amato D. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Seep Med 2005 6 : 15 22.
28. Drake CL, Roehrs TA, Mangano RM, Roth T. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. Hum Psychopharmacol 2000 15 : 595 604.
29. Hemmeter U, Müller M, Bischof R, Annen B, Holsboer-Trachsler E. Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers. Psychopharmacology 2000 147 : 384 396.
30. Feinberg I, Maloney T, Cambell IG. Effects of hypnotics on the sleep EEG of healthy young adults: New data and psychopharmacologic implications. J Psychiatr Res 2000 34 : 423 438.
31. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958 80 : 2587.
32. Dubocovich ML. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 1998 12 : 1211 1220.
33. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997 19 : 91 102.
34. Wehr TA, Aeschbach D Jr., Duncan WC. Evidence for a biological dawn and dusk in the human circadian timing system. J Physiol 2001 535 : 937 951.
35. Akerstedt T, Froberg JE, Friberg Y, Wetterberg L. Melatonin excretion, body temperature and subjective arousal during 64 hours of sleep deprivation. Psychoneuroendocrinology 1979 4 : 219 225.
36. Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996 19 : 423 431.
37. Tzischinsky O, Shlitner A, Lavie P. The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulfatoxymelatonin. J Biol Rhythms 1993 8 : 199 209.
38. Dubocovich ML. Melatonin receptors: Are there multiple subtypes? Trends Pharmacol Sci 1995 16 : 50 56.
39. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994 13 : 1177 1785.
40. 1b melatonin receptor. Proc Natl Acad Sci U S A 1995 92 : 8734 8738.
41. Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: Cloning and classification of subtypes. Trends Pharmacol Sci 1996 17 : 100 102.
42. 1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics 1995 27 : 355 357.
43. Dubocovich ML. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003 8 : d1093 d1108.
44. Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM, Weaver DR. Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol 2003 23 : 1054 1060.
45. von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 2002 309 : 151 62.
46. 125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther 1999 290 : 334 340.
47. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, Fauchere JL, Delagrange P, Canet E, Boutin JA. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000 275 : 31311 31317.
48. Nosjean O, Nicolas JP, Klupsch F, Delagrange P, Canet E, Boutin JA. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol 2001 61 : 1369 1379.
49. Miyamoto M, Nishikawa H, Doken Y, Hirai K, Uchikawa O, Ohkawa S. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004 27 : 1319 1325.
50. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: Assessment in a clinical trial of melatonin replacement. Sleep 1998 21 : 52 68.
51. Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C, Matheson JK, Schomer DL. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995 57 : 552 558.
52. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001 86 : 4727 4730.
53. Zhdanova IV, Wurtman RJ. Efficacy of melatonin as a sleep-promoting agent. J Biol Rhythms 1997 12 : 644 650.
54. Arendt J. Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 2003 15 : 427 431.
55. Arendt J, Deacon S, English J, Hampton S, Morgan L. Melatonin and adjustment to phase shift. J Sleep Res 1995 4 : 74 79.
56. Sharkey KM, Fogg LF, Eastman CI. Effects of melatonin administration on daytime sleep after simulated night shift work. J Sleep Res 2001 10 : 181 192.
57. Hardeland R, Poeggeler B, Srinivasan V, Trankht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforsung 2008 58 : 1 10.
58. Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pineal Res 1997 22 : 45 51.
59. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr 1997 24 : 223 231.
60. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomiacs. Sleep 1995 18 : 598 603.
61. Faust R, Garratt PJ, Trujillo Perez MA, Piccio VJ, Madsen C, Stenstrom A, Frolund B, Davidson K, Teh MT, Sugden D. 7-substituted-melatonin and 7-substitued-1-methylmelatonin analogues: Effect of substituents on potency and binding affinity. Bioorg Med Chem 2007 15 : 4543 4551.
62. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: The use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol 2007 3 : 221 228.
63. Rivara S, Lodola A, Mor M, Bedini A, Spandoni G, Lucini V, Pannacci M, Fraschini F, Scaglione F, Sanchez RO, et al. N-(substituted-anilinoethyl)amides: Design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem 2007 50 : 6618 6626.
64. Uchikawa O, Fukatsu K, Tokunoh R, Kawada M, Matsumoto K, Imai Y, Hinuma S, Kato K, Nishikawa H, Hirai K, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem 2002 45 : 4222 4239.
65. Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006 46 : 140 148.
66. 14C)-ramelteon (TAK-375) following a single oral dose in healthy male subjects. Sleep 2004 27 : A54.
67. Johnson MW, Suess PE, Griffiths RR. Ramelteon: A novel hypnotic lacking abuse liability and sedative side effects. Arch Gen Psychiatry 2006 63 : 1149 1157.
68. Zammit G, Schwartz H, Roth T, Wright L, Sainati S, Zhang J. Phase III study of ramelteon in a first-night-effect model of transient insomnia. Sleep Med 2005 6 : S50 S51.
69. Zammit G, Erman M, Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007 3 : 495 504.
70. 2 receptor agonist. Neuropharmacology 2005 48 : 301 310.
71. 125I] iodomelatonin labels multiple binding sites in hamster brain. Biochem Biophys Res Commun 1987 147 : 49 56.
72. Pickering DS, Niles LP. Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus. Eur J Pharmacol 1990 175 : 71 77.
73. Morgan PJ, Lawson W, Davidson G, Howell HE. Melatonin inhibits cyclic AMP in cultured ovine pars tuberalis cells. J Mol Endocrinol 1989 5 : R5 R8.
74. Vanecek J, Vollrath L. Melatonin inhibits cyclic AMP and cyclic GMP accumulation in the rat pituitary. Brain Res 1989 505 : 157 159.
75. Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Yoshikubo S, Miyamoto M. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res 2004 1027 : 59 66.
76. Daley JT, Turner RS, Freeman A, Bliwise DL, Rye DB. Prolonged assessment of sleep and daytime sleepiness in unrestrained Macaca mulatta. Sleep 2006 29 : 221 231.
77. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M. The efficacy and safety of drug treatments for chronic insomnia in adults: A meta-analysis of RCTs. J Gen Intern Med 2007 22 : 1335 1350.
78. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006 7 : 17 24.
79. Hirai K, Kita M, Ohta H, Nishikawa H, Fujiwara Y, Ohkawa S, Miyamoto M. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005 20 : 27 37.
80. Inoue S, Shimazoe T, Moriya T, Shinohara K, Miyamoto M, Watanabe S. Effects of TAK-375, a novel ML1-selective melatonin receptor agonist, on entrainment function in circadian rhythm. J Pharmacol Sci 2003 91 : 90.
81. 2 receptor agonist, on motor performance in mice. Neurosci Lett 2006 402 : 201 204.
82. Spyraki C, Fibiger HC. A role for the mesolimbic dopamine system in the reinforcing properties of diazepam. Psychopharmacology (Berl) 1988 94 : 133 137.
83. France CP, Weltman RH, Koek H, Cruz CM, McMahon LR. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): Dependence liability studies. Behav Neurosci 2006 120 : 535 541.
84. Nishida N, Sasaki M, Wakasa Y, Awasaki Y, Yamamoto M, Yanagita T. Reinforcing effect of ramelteon assessed by intravenous self-administration experiments in rhesus monkeys. Sleep 2005 28 : A5.
85. 2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005 28 : 303 307.
86. Roth T, Seiden D, Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opinion 2007 23 : 1005 1014.
87. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Medicine 2006 7 : 312 318.
88. DeMicco M, Wang-Weigand S, Zhang J. Long-term therapeutic effects of ramelteon treatment in adults with chronic insomnia: A 1-year study. Sleep 2006 29 : A234.
89. Richardson G, Wang-Weigand S, Zhang J, DeMicco M. Long-term safety of ramelteon treatment in adults with chronic insomnia: A 1-year study. Sleep 2006 29 : A233.
90. Partinen M. Epidemiology of sleep disorders. In : Kryger MH, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine, 2nd ed. Philadelphia, PA : WB Saunders, 1994 437 452.
91. Sack RL, Lewy AJ, Blood ML, Keith LD, Nakagawa H. Circadian rhythm abnormalities in totally blind people: Incidence and clinical significance. J Clin Endocrinol Metab 1992 75 : 127 134.
92. Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase response to melatonin. Lancet 1991 337 : 1121 1124.
93. Oldani A, Ferini-Strambi L, Zucconi M, Stankov B, Fraschini F, Smirne S. Melatonin and delayed sleep phase syndrome: Ambulatory polygraphic evaluation. Neuroreport 1994 6 : 132 134.
94. Nagtegaal JE, Kerkhof GA, Smits MG, Swart AC, Van Der Meer YG. Delayed sleep phase syndrome: A placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. J Sleep Res 1998 7 : 135 143.
95. Herxheimer A, Petrie KJ. Melatonin for prevention and treatment of jet lag. Cochrane Database Syst Rev 2001 1 : CD001520.
96. Crasson M, Kjiri S, Colin A, Kjiri K, L'Hermite-Baleriaux M, Ansseau M, Legros JJ. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 2004 29 : 1 12.
97. Rubin RT, Heist EK, McGeoy SS, Hanada K, Lesser IM. Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch Gen Psychiatry 1992 49 : 558 567.
98. 2c receptors antagonist, in the treatment of major depressive disorders. Encephale 2002 28 : 356 362.
99. Montgomery SA, Kasper S. Severe depression and antidepressants: Focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007 22 : 283 291.
100. Kennedy SH, Kutcher SP, Ralevski E, Brown GM. Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res 1996 63 : 219 222.
101. Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-perumal SR, Parry B, Cardinali DP. Melatonin in mood disorders. World J Biol Psychiatry 2006 7 : 138 151.
102. Nair NP, Hariharasubramanian N, Pilapil C, Isaac I, Thavundayil JX. Plasma melatonin - an index of brain aging in humans? Biol Psychiatry 1986 21 : 141 150.
103. Mirmiran M, Swaab DF, Kok JH, Hofman MA, Witting W, van Gool WA. Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. Prog Brain Res 1992 93 : 151 162.
104. Skene DJ, Vivien-Roels B, Sparks DL, Hunsaker JC, Pevet P, Ravid D, Swaab DF. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: Effect of age and Alzheimer's disease. Brain Res 1990 528 : 170 174.
105. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 2005 38 : 145 152.
106. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 2003 70 : 334 341.
107. Caldinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett 2002 23 (Suppl 20 23.
108. Mahlberg R, Kunz D, Sutej I, Kuhl KP, Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: An open-label pilot study using actigraphy. J Clin Psychopharmacol 2004 24 : 456 459.